Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.

Tonra JR, Lloyd GK, Mohanlal R, Huang L.

Cancer Chemother Pharmacol. 2020 Feb;85(2):461-468. doi: 10.1007/s00280-019-03998-w. Epub 2019 Dec 6.

PMID:
31811421
2.

Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling.

Cimino PJ, Huang L, Du L, Wu Y, Bishop J, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Carew J, Nawrocki S, Jordan MA, Wilson L, Lloyd GK, Wirsching HG.

Biomed Rep. 2019 Apr;10(4):218-224. doi: 10.3892/br.2019.1196. Epub 2019 Mar 5.

3.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 May;45(10):1356. doi: 10.1111/ejn.13573. No abstract available.

PMID:
28523903
4.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 Jan;45(1):192-197. doi: 10.1111/ejn.13435. Epub 2016 Nov 11. Erratum in: Eur J Neurosci. 2017 May;45(10 ):1356.

PMID:
27741357
5.

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA.

Neuro Oncol. 2016 Jun;18(6):840-8. doi: 10.1093/neuonc/nov299. Epub 2015 Dec 17.

6.

Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.

Yamazaki Y, Sumikura M, Masuda Y, Hayashi Y, Yasui H, Kiso Y, Chinen T, Usui T, Yakushiji F, Potts B, Neuteboom S, Palladino M, Lloyd GK, Hayashi Y.

Bioorg Med Chem. 2012 Jul 15;20(14):4279-89. doi: 10.1016/j.bmc.2012.05.059. Epub 2012 Jun 4.

PMID:
22727370
7.

Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure.

Yamazaki Y, Tanaka K, Nicholson B, Deyanat-Yazdi G, Potts B, Yoshida T, Oda A, Kitagawa T, Orikasa S, Kiso Y, Yasui H, Akamatsu M, Chinen T, Usui T, Shinozaki Y, Yakushiji F, Miller BR, Neuteboom S, Palladino M, Kanoh K, Lloyd GK, Hayashi Y.

J Med Chem. 2012 Feb 9;55(3):1056-71. doi: 10.1021/jm2009088. Epub 2012 Jan 20.

PMID:
22185476
8.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA.

Invest New Drugs. 2012 Dec;30(6):2303-17. doi: 10.1007/s10637-011-9766-6. Epub 2011 Nov 12.

PMID:
22080430
9.

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.

Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR.

Int J Radiat Biol. 2011 Nov;87(11):1126-34. doi: 10.3109/09553002.2011.605418.

10.

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA.

Invest New Drugs. 2012 Jun;30(3):1065-73. doi: 10.1007/s10637-011-9642-4. Epub 2011 Feb 16.

PMID:
21327495
11.

Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs.

Obaidat A, Weiss J, Wahlgren B, Manam RR, Macherla VR, McArthur K, Chao TH, Palladino MA, Lloyd GK, Potts BC, Enna SJ, Neuteboom ST, Hagenbuch B.

J Pharmacol Exp Ther. 2011 May;337(2):479-86. doi: 10.1124/jpet.110.177824. Epub 2011 Feb 8.

12.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. Review.

13.

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.

Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, Neuteboom ST, Cropp G, Ashton E, LoRusso PM.

Clin Cancer Res. 2010 Dec 1;16(23):5892-9. doi: 10.1158/1078-0432.CCR-10-1096.

14.

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.

Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC.

Br J Haematol. 2010 May;149(4):550-9. doi: 10.1111/j.1365-2141.2010.08144.x. Epub 2010 Mar 12.

15.

Synthesis of biotin-tagged diketopiperazine-based anti-microtubule agents and tubulin photoaffinity labeling.

Yamazaki Y, Kohno K, Yasui H, Kiso Y, Neuteboom S, Barral AM, Potts B, Lloyd GK, Hayashi Y.

Adv Exp Med Biol. 2009;611:527-8. No abstract available.

PMID:
19400297
16.

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC.

Bioorg Med Chem. 2009 Mar 15;17(6):2175-80. doi: 10.1016/j.bmc.2008.10.075. Epub 2008 Nov 5.

17.

Tubulin photoaffinity labeling with biotin-tagged derivatives of potent diketopiperazine antimicrotubule agents.

Yamazaki Y, Kohno K, Yasui H, Kiso Y, Akamatsu M, Nicholson B, Deyanat-Yazdi G, Neuteboom S, Potts B, Lloyd GK, Hayashi Y.

Chembiochem. 2008 Dec 15;9(18):3074-81. doi: 10.1002/cbic.200800317.

PMID:
19012291
18.

Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.

Manam RR, McArthur KA, Chao TH, Weiss J, Ali JA, Palombella VJ, Groll M, Lloyd GK, Palladino MA, Neuteboom ST, Macherla VR, Potts BC.

J Med Chem. 2008 Nov 13;51(21):6711-24. doi: 10.1021/jm800548b. Epub 2008 Oct 22.

PMID:
18939815
19.

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.

Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom ST.

Anticancer Drugs. 2006 Jan;17(1):25-31.

PMID:
16317287
20.

Lajollamycin, a nitro-tetraene spiro-beta-lactone-gamma-lactam antibiotic from the marine actinomycete Streptomyces nodosus.

Manam RR, Teisan S, White DJ, Nicholson B, Grodberg J, Neuteboom ST, Lam KS, Mosca DA, Lloyd GK, Potts BC.

J Nat Prod. 2005 Feb;68(2):240-3.

PMID:
15730252
21.

A new family of synthetic diterpenes that regulates cytokine synthesis by inhibiting IkappaBalpha phosphorylation.

Chao TH, Lam T, Vong BG, Través PG, Hortelano S, Chowdhury C, Bahjat FR, Lloyd GK, Moldawer LL, Boscá L, Palladino MA, Theodorakis EA.

Chembiochem. 2005 Jan;6(1):133-44.

PMID:
15540220
22.

Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.

Lam T, Ling T, Chowdhury C, Chao TH, Bahjat FR, Lloyd GK, Moldawer LL, Palladino MA, Theodorakis EA.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3217-21.

PMID:
12951096
24.
26.
27.
28.

Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization.

Quik M, Polonskaya Y, Gillespie A, Jakowec M, Lloyd GK, Langston JW.

J Comp Neurol. 2000 Sep 11;425(1):58-69.

PMID:
10940942
29.

Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist.

Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, Suto C, Washburn M, Lloyd GK, McDonald IA.

Pharm Acta Helv. 2000 Mar;74(2-3):125-30.

PMID:
10812948
30.

Neuronal nicotinic acetylcholine receptors as novel drug targets.

Lloyd GK, Williams M.

J Pharmacol Exp Ther. 2000 Feb;292(2):461-7. Review. No abstract available.

PMID:
10640281
32.

Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.

Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK.

J Pharmacol Exp Ther. 1999 Aug;290(2):731-9.

PMID:
10411585
33.

4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors.

Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, Reid R, Sacaan AI, Suto C, Washburn M, Lloyd GK, McDonald IA.

J Med Chem. 1999 May 20;42(10):1684-6. No abstract available.

PMID:
10346920
34.

Conformationally restricted analogues of nicotine and anabasine.

Vernier JM, Holsenback H, Cosford ND, Whitten JP, Menzaghi F, Reid R, Rao TS, Sacaan AI, Lloyd GK, Suto CM, Chavez-Noriega LE, Washburn MS, Urrutia A, McDonald IA.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2173-8.

PMID:
9873508
35.

Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease.

Sabbagh MN, Reid RT, Corey-Bloom J, Rao TS, Hansen LA, Alford M, Masliah E, Adem A, Lloyd GK, Thal LJ.

J Neural Transm (Vienna). 1998;105(6-7):709-17.

PMID:
9826113
36.

6-hydroxydopamine lesion of rat nigrostriatal dopaminergic neurons differentially affects nicotinic acetylcholine receptor subunit mRNA expression.

Elliott KJ, Jones JM, Sacaan AI, Lloyd GK, Corey-Naeve J.

J Mol Neurosci. 1998 Jun;10(3):251-60.

PMID:
9770646
37.

Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.

Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK.

Mov Disord. 1998 Jul;13(4):637-42.

PMID:
9686767
38.

The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.

Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M, Stauderman K, Velicelebi G, Johnson E, Harpold MM, Rao TS, Sacaan AI, Chavez-Noriega LE, Washburn MS, Vernier JM, Cosford ND, McDonald LA.

Life Sci. 1998;62(17-18):1601-6. Review.

PMID:
9585143
39.
40.

Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.

Williams M, Wright S, Lloyd GK.

Trends Pharmacol Sci. 1997 Sep;18(9):307-10. No abstract available.

PMID:
9345846
42.

Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.

PMID:
8996220
43.

Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):384-92.

PMID:
8996219
44.

Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.

Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):373-83.

PMID:
8996218
45.

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.

Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA.

J Med Chem. 1996 Aug 16;39(17):3235-7. No abstract available.

PMID:
8765504
46.
47.

Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.

Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK.

J Pharmacol Exp Ther. 1996 Feb;276(2):509-15.

PMID:
8632316
49.

The GABAA-like autoreceptor is a pharmacologically novel GABA receptor.

Minchin MC, Ennis C, Lattimer N, White JF, White AC, Lloyd GK.

Adv Biochem Psychopharmacol. 1992;47:199-203. No abstract available.

PMID:
1324573
50.

GABAA receptor complex function in frontal cortex membranes from control and neurological patients.

Lloyd GK, Lowenthal A, Javoy-Agid F, Constantidinis J.

Eur J Pharmacol. 1991 May 2;197(1):33-9.

PMID:
1654259

Supplemental Content

Loading ...
Support Center